Literature DB >> 28461024

Care management in amyotrophic lateral sclerosis.

M-H Soriani1, C Desnuelle2.   

Abstract

Amyotrophic lateral sclerosis (ALS) is a relentlessly progressive and fatal neurodegenerative disease characterized by progressive weakness of voluntary muscles of movement as well as those for swallowing, speech and respiration. In the absence of curative treatment, care can improve quality of life, prolong survival, and support ALS patients and their families, and also help them to anticipate and prepare for the end of life. Multidisciplinary management in tertiary centers is recommended in close collaboration with general practitioners, home carers and a dedicated health network. Patients' follow-up deals mainly with motor impairment and physical disability, adaptation, nutrition and respiratory function. Involvement of palliative care as part of the multidisciplinary team management offers patients the possibility of discussing their end of life issues. This review summarizes the different aspects of ALS care, from delivering the diagnosis to the end of life, and the organization of its management.
Copyright © 2017 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  ALS management; Amyotrophic lateral sclerosis; Ethics; Non-invasive ventilation; Nutrition; Palliative care; Rehabilitation

Mesh:

Year:  2017        PMID: 28461024     DOI: 10.1016/j.neurol.2017.03.031

Source DB:  PubMed          Journal:  Rev Neurol (Paris)        ISSN: 0035-3787            Impact factor:   2.607


  7 in total

1.  Prevalence of amyotrophic lateral sclerosis in the United States using established and novel methodologies, 2017.

Authors:  Paul Mehta; Jaime Raymond; Reshma Punjani; Moon Han; Theodore Larson; Wendy Kaye; Lorene M Nelson; Barbara Topol; Oleg Muravov; Corina Genson; D Kevin Horton
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2022-04-15       Impact factor: 3.528

Review 2.  Emerging Novel Approaches for the Enhanced Delivery of Natural Products for the Management of Neurodegenerative Diseases.

Authors:  Akshay Bandiwadekar; Jobin Jose; Maryam Khayatkashani; Solomon Habtemariam; Hamid Reza Khayat Kashani; Seyed Mohammad Nabavi
Journal:  J Mol Neurosci       Date:  2021-10-25       Impact factor: 3.444

Review 3.  TDP-43 as a potential biomarker for amyotrophic lateral sclerosis: a systematic review and meta-analysis.

Authors:  Vivek Majumder; Jenna M Gregory; Marcelo A Barria; Alison Green; Suvankar Pal
Journal:  BMC Neurol       Date:  2018-06-28       Impact factor: 2.474

4.  Current status and direct medical cost of amyotrophic lateral sclerosis in the region of Catalonia: A population-based analysis.

Authors:  Josep Darbà
Journal:  PLoS One       Date:  2019-10-11       Impact factor: 3.240

5.  Use of a modular ontology and a semantic annotation tool to describe the care pathway of patients with amyotrophic lateral sclerosis in a coordination network.

Authors:  Sonia Cardoso; Pierre Meneton; Xavier Aimé; Vincent Meininger; David Grabli; Gilles Guezennec; Jean Charlet
Journal:  PLoS One       Date:  2021-01-06       Impact factor: 3.240

Review 6.  An Overview of PDE4 Inhibitors in Clinical Trials: 2010 to Early 2022.

Authors:  Letizia Crocetti; Giuseppe Floresta; Agostino Cilibrizzi; Maria Paola Giovannoni
Journal:  Molecules       Date:  2022-08-04       Impact factor: 4.927

Review 7.  Organ on a Chip: A Novel in vitro Biomimetic Strategy in Amyotrophic Lateral Sclerosis (ALS) Modeling.

Authors:  Babak Arjmand; Shayesteh Kokabi Hamidpour; Zahra Rabbani; Akram Tayanloo-Beik; Fakher Rahim; Hamid Reza Aghayan; Bagher Larijani
Journal:  Front Neurol       Date:  2022-01-17       Impact factor: 4.003

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.